Constitutive expression of the chimeric
NPM/ALK fusion protein encoded by the t(2;5)(p32;q35) is a key oncogenic event in the pathogenesis of most
anaplastic large cell lymphomas (ALCLs). The proteomic network alterations produced by this aberration remain largely uncharacterized. Using a mass spectrometry (MS)-driven approach to identify changes in
protein expression caused by the
NPM/ALK fusion, we identified diverse
NPM/ALK-induced changes affecting cell proliferation, ribosome synthesis, survival, apoptosis evasion, angiogenesis, and cytoarchitectural organization. MS-based findings were confirmed using Western blotting and/or immunostaining of
NPM/ALK-transfected cells and ALK-deregulated
lymphomas. A subset of the
proteins distinguished
NPM/ALK-positive ALCLs from
NPM/ALK-negative ALCLs and
Hodgkin lymphoma. The multiple
NPM/ALK-deregulated pathways identified by MS analysis also predicted novel
biologic effects of
NPM/ALK expression. In this regard, we showed loss of cell adhesion as a consequence of
NPM/ALK expression in a
kinase-dependent manner, and sensitivity of
NPM/ALK-positive ALCLs to inhibition of the RAS, p42/44ERK, and FRAP/mTOR signaling pathways. These findings reveal that the
NPM/ALK alteration affects diverse cellular pathways, and provide novel insights into
NPM/ALK-positive ALCL pathobiology. Our studies carry important implications for the use of MS-driven approaches for the elucidation of neoplastic pathobiology, the identification of novel diagnostic
biomarkers, and pathogenetically relevant therapeutic targets.